FOLH1 and prostate carcinoma: Compared to conventional imaging, PSMA PET radiopharmaceuticals have been shown to be more accurate, sensitive, and specific at identifying pelvic nodal or distant metastatic disease when used in primary staging of high-risk prostate cancer and lead to more management changes as seen in the ProPSMA study [11].